Joseph Papa steps down as chair and will remain at helm and on board until successor appointed. Guggenheim analysts reported representatives on B+L board for activist investor Carl Icahn appointed a month ago likely led to Papa’s exit.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Consumer health product firms’ vistas include challenges of supply chain disruptions lingering from pandemic’s impact as well as potential for marketplace restrictions as additional varieties of the novel coronavirus spread. Clouds also include shifts in consumer spending, increases in costs caused by inflation and foreign exchange headwinds as the value of the US dollar strengthens against other currencies.

FDA history with emergency contraceptives and opioid overdose antidote naloxone doesn’t assure Jeffrey Singer, Valley Surgical Clinics founder and advocate for making more drugs available OTC, the agency will approve HRA Pharma's NDA for OTC 0.075-mg norgestrel.